EUROPE

IFS and HOIST launch FLEXPLUS Enterprise Applications Services

Retrieved on: 
Tuesday, June 13, 2023
Data management, Pressure, DNA, Partnership, Ecosystem, System, Financial adviser, Retail, Online shopping, EUROPE

LONDON, June 13, 2023 /PRNewswire/ -- IFS, the global enterprise applications company, has today announced that it has partnered with HOIST, already a strategic partner in the IFS Ecosystem, to develop and deliver a mid-market specialised service offering to help further drive customer satisfaction in the IFS ecosystem. 

Key Points: 
  • LONDON, June 13, 2023 /PRNewswire/ -- IFS, the global enterprise applications company, has today announced that it has partnered with HOIST, already a strategic partner in the IFS Ecosystem, to develop and deliver a mid-market specialised service offering to help further drive customer satisfaction in the IFS ecosystem.
  • The goal for FLEXPLUS is to ensure that, regardless of their own capabilities, customers are realising value along the journey.
  • As a strategic IFS Partner, HOIST is committing to invest to maintain and develop capabilities, in line with IFS solution developments, therefore reducing the customer overheads associated with this.
  • FLEXPLUS is a flexible lifecycle support program offered to IFS mid-size customers worldwide, particularly tailored toward customers that require a high touch, low volume engagement with IFS experts.

EQS-News: SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX.

Retrieved on: 
Saturday, June 10, 2023
EUROPE, CFO, DAX, Sevenum, SHOP, MDAX, Retail

SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX.

Key Points: 
  • SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX.
  • SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX.
  • SHOP APOTHEKE EUROPE will be promoted to the MDAX, the leading German stock index for mid-sized companies, following the latest index review by global index provider STOXX Ltd.
  • Effective 19 June 2023, SHOP APOTHEKE EUROPE will be among the 50 largest listed companies in Germany based on free float market capitalisation, just behind the top 40 companies in the DAX.

Leonteq AG: Leonteq launches three ETPs+ on the Finanz und Wirtschaft Index Family

Retrieved on: 
Monday, June 5, 2023
ETP, FINMA, EUROPE, Saturday, New South Wales Rugby Union, Carbon, MSCI, Investment, Risk, SIX Swiss Exchange, CHF, SIX, Safety, Bank, Asset management, Cryptocurrency, Security (finance), Leonteq

Leonteq and Finanz und Wirtschaft (FuW) are further expanding their successful collaboration following the launch of a series of investment products which recorded a solid interest among investors and are now launching three new ETPs+ respectively on the FuW Risk Portfolio Index NTR, FuW Value Portfolio Index NTR and FuW Eco Portfolio Index NTR.

Key Points: 
  • Leonteq and Finanz und Wirtschaft (FuW) are further expanding their successful collaboration following the launch of a series of investment products which recorded a solid interest among investors and are now launching three new ETPs+ respectively on the FuW Risk Portfolio Index NTR, FuW Value Portfolio Index NTR and FuW Eco Portfolio Index NTR.
  • Alessandro Ricci, Head Investment Solutions of Leonteq, states: “We are pleased to announce the expansion of our cooperation with Finanz und Wirtschaft, a leading Swiss editorial group.
  • Founded in 1928, Finanz und Wirtschaft is aimed at savvy private and professional investors who work in or with the global financial markets.
  • Learn more about the ETPs+ linked to the FuW Risk Portfolio Index, FuW Value Portfolio Index and FuW Eco Portfolio Index.

AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

Retrieved on: 
Thursday, June 1, 2023
Science, US Foods, SG, JP, European Medicines Agency, Policy, Calendar, KOREA, IP, EMA, US, NOA, Patent, FDA, Health Canada, ALS, Masitinib, Food, AU, Pharmaceutical industry, EUROPE

A NOA is issued after an examiner determines that a patent application satisfies all requirements for patentability.

Key Points: 
  • A NOA is issued after an examiner determines that a patent application satisfies all requirements for patentability.
  • In addition to patent protection, masitinib is also eligible for regulatory data protection in Canada, preventing generic competition for a period of 8 years following initial approval.
  • As a reminder, Health Canada had granted authorization to file a new drug submission for masitinib in the treatment of ALS under the notice of compliance with conditions (NOC/c) policy.
  • On May 9, 2023, AB Science announced that Health Canada had resumed its review of the application of masitinib in the treatment of ALS.

EQS-News: Joint Venture Approved: SHOP APOTHEKE EUROPE and Galenica Create the Leading Online Pharmacy in Switzerland.

Retrieved on: 
Thursday, May 11, 2023
Online, Venture, Partnership, Sevenum, SHOP, EUROPE, Plasma protein binding, Acquisition, Patient, Health, Grocery store, Retail, Galenica

Joint Venture Approved: SHOP APOTHEKE EUROPE and Galenica Create the Leading Online Pharmacy in Switzerland.

Key Points: 
  • Joint Venture Approved: SHOP APOTHEKE EUROPE and Galenica Create the Leading Online Pharmacy in Switzerland.
  • Joint Venture Approved: SHOP APOTHEKE EUROPE and Galenica Create the Leading Online Pharmacy in Switzerland.
  • The competition authorities in Switzerland and Austria confirmed the approval for the joint venture between SHOP APOTHEKE EUROPE and Galenica today.
  • In late March 2023, SHOP APOTHEKE EUROPE, Europe’s leading online pharmacy and Galenica, Switzerland's leading integrated healthcare service provider, announced the establishment of a joint venture as part of a strategic partnership.

EQS-News: SHOP APOTHEKE EUROPE: STRONG Q1 WITH 22% SALES GROWTH AND EBITDA MARGIN IN UPPER PART OF FULL-YEAR GUIDANCE.

Retrieved on: 
Tuesday, May 2, 2023
Saskatchewan River Sturgeon Management Board, Partnership, International, Sevenum, SHOP, Marketing, S&D, Bank statement, SALES, EUROPE, Annual, Annual general meeting, Stock exchange, EBIT, Element, NPS, EUR, MSCI, SAE, EBITDA, Metropolitan Stock Exchange, AAA, RDC, Growth, ESG, Galenica, AA, Shoemaking, Film industry, Cryptocurrency, Retail, Distribution (marketing), Lithium, DACH

SHOP APOTHEKE EUROPE: STRONG Q1 WITH 22% SALES GROWTH AND EBITDA MARGIN IN UPPER PART OF FULL-YEAR GUIDANCE.

Key Points: 
  • SHOP APOTHEKE EUROPE: STRONG Q1 WITH 22% SALES GROWTH AND EBITDA MARGIN IN UPPER PART OF FULL-YEAR GUIDANCE.
  • SHOP APOTHEKE EUROPE: STRONG Q1 WITH 22% SALES GROWTH AND EBITDA MARGIN IN UPPER PART OF FULL-YEAR GUIDANCE.
  • EBITDA margin 2.4%, 3.8 pp better than Q1 2022; upper part of the full-year guidance of 0.5 to 2.5%.
  • Not only sales growth, but also the adjusted EBITDA margin was the highest since early 2021.

EQS-News: Successful Outcome for SHOP APOTHEKE EUROPE's Annual General Meeting 2023: Approval of New CEO and Change of Corporate Name.

Retrieved on: 
Friday, April 28, 2023
Pharmacy, SHOP, Frankfurt Stock Exchange, EUROPE, Annual, Annual general meeting, Red, SAE, Change, RDC, CFO, Management, Grocery store

Successful Outcome for SHOP APOTHEKE EUROPE's Annual General Meeting 2023: Approval of New CEO and Change of Corporate Name.

Key Points: 
  • Successful Outcome for SHOP APOTHEKE EUROPE's Annual General Meeting 2023: Approval of New CEO and Change of Corporate Name.
  • Successful Outcome of SHOP APOTHEKE EUROPE's Annual General Meeting 2023: Approval of New CEO and Change of Corporate Name.
  • At the Annual General Meeting on 26 April 2023, the appointment of the new CEO Olaf Heinrich was approved.
  • At the Annual General Meeting, investors also approved the change of the company name from SHOP APOTHEKE EUROPE N.V. to Redcare Pharmacy N.V.

AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

Retrieved on: 
Tuesday, April 18, 2023
US Foods, SG, European Medicines Agency, MOST, THIS, EMA, US, Euronext, NOA, Patent, FDA, ALS, Masitinib, Food, AU, Pharmaceutical industry, EUROPE

AB SCIENCE ANNOUNCES MASITINIB PATENT GRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2037

Key Points: 
  • AB SCIENCE ANNOUNCES MASITINIB PATENT GRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2037
    TO DATE, THIS PATENT HAS BEEN GRANTED IN 12 REGIONS INCLUDING EUROPE, USA, CHINA, ISRAEL AND MOST RECENTLY JAPAN
    AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib (JP 2022037132A).
  • As a result, intellectual property protection for masitinib is secured in ALS until 2037.
  • An NOA is issued after an examiner determines that a patent application satisfies all requirements for patentability.
  • This new patent provides strong protection for masitinib in the treatment of ALS until 2037 in the key geographic areas where masitinib could be marketed.”

EQS-News: SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.

Retrieved on: 
Saturday, April 15, 2023
International, Sevenum, STRONG, SHOP, EUROPE, NPS, EUR, Fast food, Film industry, DACH

SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.

Key Points: 
  • SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.
  • SHOP APOTHEKE EUROPE: VERY STRONG START TO YEAR, FASTEST GROWTH SINCE EARLY 2021.
  • SHOP APOTHEKE EUROPE’s CEO Stefan Feltens comments: “We have had a phenomenal start to the year, with non-Rx sales growth of well above 20% and double-digit sales growth in each of our seven countries.
  • SHOP APOTHEKE EUROPE N.V. will release the full interim report for the first quarter of 2023 on 2 May 2023.

EQS-News: SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.

Retrieved on: 
Friday, March 31, 2023
Partnership, CET, SHOP, Pharmacy, Bank statement, EUROPE, Central European Time, CCO, Sale, Plasma protein binding, EUR, EBITDA, VWAP, Patient, Webcast, Health, CHF, Conference, Distribution (marketing), Security (finance), Retail, Cryptocurrency, Commercial property

SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.

Key Points: 
  • SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.
  • SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.
  • SHOP APOTHEKE EUROPE is the leading e-pharmacy in Europe and operates a rapidly growing digital health platform in Switzerland with shop-apotheke.ch.
  • Net, SHOP APOTHEKE EUROPE pays to GALENICA 1.2 million shares (number is rounded) of SHOP APOTHEKE EUROPE for the overall transaction.